A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years
Brief Summary
This study was a Phase 1, double-blind, placebo-controlled, randomised study of very low dose LSD. Healthy volunteers aged 55 to 75 years with no use of LSD in the past 5 years were screened within 28 days of randomization. Subjects who met all inclusion and no exclusion criteria and provided written informed consent were randomised a 1:1:1:1 ratio to receive 6 doses of 5 µg, 10 µg, or 20 µg LSD or placebo, at 4-day intervals for 21 days (on Study Days 1, 5, 9, 13, 17, and 21). A follow-up visit was conducted approximately 4 weeks after the last dose of LSD. A total of 48 subjects were enrolled.
Intervention / Treatment
-
Drug: Lysergic acid diethylamide (LSD) 5µg
-
Drug: Lysergic acid diethylamide (LSD) 10µg
-
Drug: Lysergic acid diethylamide (LSD)20 µg
-
Drug: Placebo
Condition or Disease
- Healthy Volunteers
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 55 Years to 75 Years (Adult, Older Adult) |
| Enrollment: | 48 () |
| Funded by: | Industry |
Masking |
|
Clinical Trial Dates
| Start date: | Jun 29, 2015 | |
|---|---|---|
| Primary Completion: | Oct 30, 2015 | |
| Completion Date: | Nov 05, 2015 | |
| Study First Posted: | Jun 09, 2020 | |
| Results First Posted: | Sep 25, 2020 | |
| Last Updated: | Jun 09, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
The magnitude of the effect of LSD was explored across specific PD measures.
These included:
- Cognition and affect, including evaluation of memory, temporal perception, executive function, and learning
- Subjective effects
- Proprioception and balance
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 55 |
| Maximum Age: | 75 |
More Details
| NCT Number: | NCT04421105 |
|---|---|
| Other IDs: | CAS-50-37-3-01 |
| Study URL: | https://ClinicalTrials.gov/show/NCT04421105 |
Last updated: Jan 27, 2021